The US Food and Drug Administration granted CSPC Pharmaceutical (HKG:1093) fast track designation for its CPO301 treatment for lung cancer patients, according to a Tuesday filing with the Hong Kong Exchange.
The drug is indicated for patients with recurrent or metastatic squamous non-small cell lung cancer with an overexpression of epidermal growth factor receptor despite platinum-based chemotherapy, among other therapies, the filing said.
Price (HKD): $7.04, Change: $-0.080, Percent Change: -1.12%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。